On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
, A., Clinical and Experimental Medicine, doi:10.1007/s10238-023-01010-7, Feb 2023
Letter to the editor discussing the choice of molnupiravir and paxlovid as the only approved COVID-19 antiviral therapies in Australia in 2022, despite other therapies showing higher efficacy and lower cost in clinical trials. The author questions why better performing therapies were prevented and notes that the government should follow the science in selecting therapies. The author also compares COVID-19 fatalities in the US, UAE, and worldwide average, suggesting the UAE had lower fatalities due to permitting antiviral therapies that were obstructed in the US and Australia.
Study covers paxlovid and molnupiravir.
1.
Shen et al., Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection, Pharmaceutics, doi:10.3390/pharmaceutics17070832.
2.
Vukovikj et al., Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024, Eurosurveillance, doi:10.2807/1560-7917.ES.2025.30.10.2400252.
3.
Brewitz et al., Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.4c01342.
4.
Lopez et al., SARS-CoV-2 Resistance to Small Molecule Inhibitors, Current Clinical Microbiology Reports, doi:10.1007/s40588-024-00229-6.
Boretti et al., 8 Feb 2023, preprint, 1 author.
Contact: a.a.boretti@gmail.com.
Abstract: Clinical and Experimental Medicine (2023) 23:4033–4034
https://doi.org/10.1007/s10238-023-01010-7
CORRESPONDENCE
On the choice of Molnupiravir and Paxlovid as the only antivirals
permitted for COVID‑19 infection in Australia
Alberto Boretti1
Received: 14 January 2023 / Accepted: 23 January 2023 / Published online: 8 February 2023
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023
To the Editor,
Australia has prohibited to use the of COVID-19 antiviral therapies which were prohibited in Europe and North
America, despite countries permitting these therapies to
achieve much lower fatalities due to COVID-19 infection.
Then, in 2022, with COVID-19 starting to be downgraded
in many jurisdictions to the normal flu, with about the same
of flu fatalities, irrespective of vaccination status, Australia
finally permitted two antiviral drugs, which are not the more
effective, nor the cheaper in between those with trial information in the scientific literature, and only for selected categories (Fig. 1). The permitted oral treatment is Lagevrio
(Molnupiravir) and Paxlovid (nirmatrelvir and ritonavir).
According to the database of c19early.org [1], collecting all
the published data of all the trials about COVID-19 therapies, currently (January 2023) 36 of 48 treatments analyzed show statistically significant efficacy or harm, defined
as ≥ 10% decreased risk or > 0% increased risk from ≥ 3
studies. Paxlovid, listed since the second half of 2022, has
delivered so far an improvement of 40% based on 20 studies
including 26,783 patients. One treatment costs US$ 529. It
is ranked no. 20 for efficacy in All studies (pooled effects, all
stages). Molnupiravir, listed since the second half of 2021,
has delivered so far an improvement of 20% based on 25
studies including 69,837 patients. One treatment costs US$
707. It is ranked no. 41 for efficacy in All studies. Technically, at the time of approval in Australia [2], there was not
Fig. 1 Timeline of introduction
of COVID-19 therapies according to www.c19early.org [1].
Credit www.c19early.org
* Alberto Boretti
a.a.boretti@gmail.com
1
Johnsonville Road, Johnsonville, 6037 Wellington ,
New Zealand
13
Vol.:(0123456789)
4034
Clinical and Experimental Medicine (2023) 23:4033–4034
Fig. 2 Daily new COVID19 deaths per million people
according to www.ourworldin
data.org [3]. Credit www.ourwo
rldindata.org
enough data to support the use of Paxlovid. The Australian
government signed a contract with Merck Sharp & Dohme’s
(MSD) for the supply of Lagevrio, and with Pfizer for Paxlovid. The rank of c19study suffers from the time of the
introduction of one therapy, as the initial COVID-19 virus
was much less infectious but much more lethal than the latest
variants, of much-reduced lethality but increased infectivity,
as it was with the Spanish Flu, Fig. 2 [3]. The graph compares the fatalities in the United States and the United Arab
Emirates with the world average. The United Arab Emirates permitted since the beginning of the pandemic the use
of antiviral therapies which were otherwise obstructed in
the United States and Australia, also in the early stages of
infection [4, 5]. Therapies more recently introduced, such
as Molnupiravir and especially Paxlovid, are advantaged vs.
those introduced earlier. Why better performing therapies
were and are prevented, and why this selection, is a scientific
mystery. Should not the government follow science in the
selection of..
DOI record:
{
"DOI": "10.1007/s10238-023-01010-7",
"ISSN": [
"1591-9528"
],
"URL": "http://dx.doi.org/10.1007/s10238-023-01010-7",
"alternative-id": [
"1010"
],
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "14 January 2023"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "23 January 2023"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 3,
"value": "8 February 2023"
},
{
"group": {
"label": "Declarations",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 1
},
{
"group": {
"label": "Conflict of interest",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 2,
"value": "The authors declare no competing interests."
},
{
"label": "Free to read",
"name": "free",
"value": "This content has been made available to all."
}
],
"author": [
{
"affiliation": [],
"family": "Boretti",
"given": "Alberto",
"sequence": "first"
}
],
"container-title": "Clinical and Experimental Medicine",
"container-title-short": "Clin Exp Med",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T18:25:07Z",
"timestamp": 1675880707000
},
"deposited": {
"date-parts": [
[
2023,
10,
31
]
],
"date-time": "2023-10-31T20:07:01Z",
"timestamp": 1698782821000
},
"indexed": {
"date-parts": [
[
2023,
11,
1
]
],
"date-time": "2023-11-01T06:30:17Z",
"timestamp": 1698820217290
},
"is-referenced-by-count": 0,
"issue": "7",
"issued": {
"date-parts": [
[
2023,
2,
8
]
]
},
"journal-issue": {
"issue": "7",
"published-online": {
"date-parts": [
[
2023,
11
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T00:00:00Z",
"timestamp": 1675814400000
}
},
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T00:00:00Z",
"timestamp": 1675814400000
}
}
],
"link": [
{
"URL": "https://link.springer.com/content/pdf/10.1007/s10238-023-01010-7.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/article/10.1007/s10238-023-01010-7/fulltext.html",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/content/pdf/10.1007/s10238-023-01010-7.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"page": "4033-4034",
"prefix": "10.1007",
"published": {
"date-parts": [
[
2023,
2,
8
]
]
},
"published-online": {
"date-parts": [
[
2023,
2,
8
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"key": "1010_CR1",
"unstructured": "www.c19early.org"
},
{
"key": "1010_CR2",
"unstructured": "www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/two-anti-viral-covid-19-treatments-approved"
},
{
"key": "1010_CR3",
"unstructured": "www.ourworldindata.org"
},
{
"author": "A Boretti",
"first-page": "794",
"issue": "5",
"journal-title": "J Taibah Univ Med Sci",
"key": "1010_CR4",
"unstructured": "Boretti A. Pharmacotherapy for COVID-19 infection in the countries of the Cooperation Council for the Arab States. J Taibah Univ Med Sci. 2021;16(5):794.",
"volume": "16",
"year": "2021"
},
{
"author": "A Boretti",
"first-page": "256",
"issue": "3",
"journal-title": "Signa Vitae",
"key": "1010_CR5",
"unstructured": "Boretti A. Analysis of the performances of the covid-19 therapeutic approaches in the United Arab Emirates. Signa Vitae. 2021;17(3):256–63.",
"volume": "17",
"year": "2021"
},
{
"key": "1010_CR6",
"unstructured": "www.health.gov.au/health-alerts/covid-19/treatments/eligibility#eligibility-for-oral-covid19-treatments"
}
],
"reference-count": 6,
"references-count": 6,
"relation": {},
"resource": {
"primary": {
"URL": "https://link.springer.com/10.1007/s10238-023-01010-7"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
"volume": "23"
}